Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions

Original research
par
Bouck, Zachary et al

Date de publication

2022

Géographie

Canada

Langue de la ressource

English

Texte disponible en version intégrale

Non

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

We used segmented regression analyses to evaluate the joint effects of the provincial COVID-19 emergency declaration, federal OAT exemptions, and interim treatment guidance—all implemented between March 17th–23rd, 2020—on the weekly proportion of participants enrolled in OAT (i.e., ≥1 day(s) covered with methadone or buprenorphine/naloxone), with an opioid-related overdose (based on emergency department visits and hospitalizations), and who died (all-cause), and the weekly proportion of OAT-enrolled participants receiving take-home doses (i.e., ≥1 day(s) covered) and undergoing urine drug screening.

Constatations/points à retenir

Changes to OAT provision following provincial COVID-19 restrictions were associated with an immediate and sustained increase in take-home dose coverage among OAT-enrolled participants, without corresponding increases in opioid-related overdoses among all participants.

La conception ou méthodologie de recherche

Interrupted time series using administrative data (n=359)

Mots clés

Transitions in care/treatment
Policy/Regulatory
Evidence base
Outcomes
Overdose
Mortality
About PWUD